1. Home
  2. TBI vs MOLN Comparison

TBI vs MOLN Comparison

Compare TBI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TrueBlue Inc.

TBI

TrueBlue Inc.

HOLD

Current Price

$5.66

Market Cap

129.9M

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$3.84

Market Cap

144.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBI
MOLN
Founded
1985
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Professional Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
129.9M
144.0M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
TBI
MOLN
Price
$5.66
$3.84
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$6.00
$8.38
AVG Volume (30 Days)
400.9K
1.9K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
61.39
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.25
N/A
Revenue Next Year
$3.90
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$3.41
52 Week High
$7.78
$5.36

Technical Indicators

Market Signals
Indicator
TBI
MOLN
Relative Strength Index (RSI) 62.42 35.66
Support Level $5.43 $3.52
Resistance Level $6.41 $3.97
Average True Range (ATR) 0.50 0.08
MACD -0.01 -0.04
Stochastic Oscillator 49.75 5.09

Price Performance

Historical Comparison
TBI
MOLN

About TBI TrueBlue Inc.

TrueBlue Inc is a provider of specialized workforce solutions that connect employers with talent. Its reportable segments include PeopleReady, which provides blue-collar contingent staffing and delivers on-demand and skilled labor across industries such as construction, transportation, retail, hospitality, and energy. The PeopleManagement segment offers contingent labor and outsourced industrial workforce solutions, mainly on-site at client facilities, through its OnSite and Centerline operations, focusing on workforce management and commercial driver services. PeopleSolutions delivers services focused on professional and specialized talent acquisition, as well as workforce management and compliance. The company generates the majority of its revenue from the PeopleReady segment.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: